Mark A Ritter
Overview
Explore the profile of Mark A Ritter including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
633
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Basree M, Witt J, Uboha N, Lubner M, Minter R, Weber S, et al.
Pract Radiat Oncol
. 2025 Feb;
PMID: 39924052
Background And Purpose: Elective nodal irradiation (ENI) in resectable pancreatic cancer remains undefined, though occult nodal disease is common. This study investigated the use of neoadjuvant stereotactic body radiation therapy...
2.
Morris B, Holmes E, Anger N, Cooley G, Schuster J, Hurst N, et al.
Int J Radiat Oncol Biol Phys
. 2023 May;
117(3):613-623.
PMID: 37179035
Purpose: In this prospective phase 2 trial, we investigated the toxicity and patient-reported quality-of-life outcomes in patients treated with stereotactic body radiation therapy (SBRT) to the prostate gland and a...
3.
Witt J, Kuczmarska-Haas A, Lubner M, Reeder S, Cho S, Minter R, et al.
Int J Radiat Oncol Biol Phys
. 2020 Sep;
109(2):458-463.
PMID: 32942002
Purpose: The role of neoadjuvant radiation for resectable pancreatic adenocarcinoma is controversial. We performed a prospective dose-escalation study of neoadjuvant stereotactic body radiation therapy (SBRT) with concurrent capecitabine and elective...
4.
Ritter M, Kupelian P, Petereit D, Lawton C, Anger N, Geye H, et al.
Pract Radiat Oncol
. 2020 Mar;
10(5):345-353.
PMID: 32169590
Purpose: This phase I/II, multi-institutional trial explored the tolerance and efficacy of stepwise increasing hypofractionation (HPFX) radiation therapy regimens for fraction sizes up to 4.3 Gy in localized prostate cancer....
5.
Witt J, Jagodinsky J, Liu Y, Yadav P, Kuczmarska-Haas A, Yu M, et al.
Am J Clin Oncol
. 2019 Jul;
42(8):662-667.
PMID: 31313677
Purpose: The purpose of this study was to evaluate predictors of cardiac events in esophageal cancer patients treated with neoadjuvant chemoradiotherapy (NA CRT) followed by surgery compared with surgery alone....
6.
Etheridge T, Straus J, Ritter M, Jarrard D, Huang W
Urol Oncol
. 2018 Oct;
36(12):532.e1-532.e7.
PMID: 30337219
Background: Alpha methylacyl A coenzyme racemase (AMACR) has shown to be an excellent immunohistological biomarker for prostate cancer (CaP). Given the connection between prostate and urethra, we hypothesized that semen...
7.
Harari P, Ritter M, van der Kogel A
Int J Radiat Oncol Biol Phys
. 2017 Mar;
97(5):886-888.
PMID: 28333004
No abstract available.
8.
Johnson S, Soulos P, Shafman T, Mantz C, Dosoretz A, Ross R, et al.
Radiother Oncol
. 2016 Nov;
121(2):294-298.
PMID: 27890426
Background And Purpose: Evaluate changes in bowel, urinary and sexual patient-reported quality of life following treatment with moderately hypofractionated radiotherapy (<5Gray/fraction) or stereotactic body radiation therapy (SBRT;5-10Gray/fraction) for prostate cancer....
9.
Brower J, Chen S, Bassetti M, Yu M, Harari P, Ritter M, et al.
Int J Radiat Oncol Biol Phys
. 2016 Nov;
96(5):985-993.
PMID: 27869098
Purpose: To evaluate the effect of radiation dose escalation on overall survival (OS) for patients with nonmetastatic esophageal cancer treated with concurrent radiation and chemotherapy. Methods And Materials: Patients diagnosed...
10.
Morris Z, Saha S, Magnuson W, Morris B, Borkenhagen J, Ching A, et al.
Cancer
. 2016 May;
122(16):2487-95.
PMID: 27203227
Background: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are commonly used antihypertensive medications that have been reported to affect aberrant angiogenesis and the dysregulated inflammatory response. Because of...